» Articles » PMID: 23600685

Epigenetic Regulation of Pregnane X Receptor Activity

Overview
Journal Drug Metab Rev
Publisher Informa Healthcare
Specialty Pharmacology
Date 2013 Apr 23
PMID 23600685
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Pregnane X receptor (PXR, NR1I2) is a ligand-dependent nuclear receptor (NR) that functions as a xenobiotic sensor and effector in coordinately regulating expression of genes of the xenobiotic detoxification network. PXR exerts its transcriptional regulatory functions by dimerization with retinoic X receptor RXR, and PXR-RXR complex binds to specific DNA sequences for regulating gene expression. PXR functions are regulated at the epigenetic level by chromatin modifications, DNA methylation and noncoding RNA. Chromatin modifications are carried out, in part, through interaction with coregulator complexes, including steroid coactivators (SRCs), corepressors (NcoR/SMRT), hepatocyte nuclear factor 4 alpha, proliferator activated receptor γ coactivator 1 alpha and protein arginine methyltransferase 1. PXR can be modified by acetylation, phosphorylation and sumoylation, and the promoter of PXR can be methylated at the "CpG" island. These factors collectively determine the ways in which PXR activity can be regulated, thereby affecting the magnitude and duration of the PXR-regulated drug metabolic responses. Most studies of PXR focus on its role as a transcription factor, which is responsible for the generation of messenger RNA. Recent emerging evidence suggests that PXR regulates gene expression at both transcriptional and translational levels. This review highlights recent research on the epigenetic mechanisms that are found to be important for the gene-regulatory activity of PXR and discusses their implications in xenobiotic metabolism and adverse drug responses.

Citing Articles

Gut microbiota trigger host liver immune responses that affect drug-metabolising enzymes.

Rao J, Qiu P, Zhang Y, Wang X Front Immunol. 2024; 15:1511229.

PMID: 39720713 PMC: 11668346. DOI: 10.3389/fimmu.2024.1511229.


Roles of and polymorphisms in the susceptibility to antituberculosis drug-induced liver injury in China: a case‒control study.

Xu X, Chen R, Lu L, Cheng J, He X, Pan H Front Genet. 2024; 15:1428319.

PMID: 39512799 PMC: 11541836. DOI: 10.3389/fgene.2024.1428319.


Pharmacokinetics, Pharmacodynamics, and Side Effects of Midazolam: A Review and Case Example.

Peter J, Dieudonne P, Zolk O Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675433 PMC: 11054797. DOI: 10.3390/ph17040473.


Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.

Niu X, Wu T, Yin Q, Gu X, Li G, Zhou C Cells. 2022; 11(19).

PMID: 36231056 PMC: 9563422. DOI: 10.3390/cells11193094.


Gut microbiota-derived metabolite 3-idoleacetic acid together with LPS induces IL-35 B cell generation.

Su X, Zhang M, Qi H, Gao Y, Yang Y, Yun H Microbiome. 2022; 10(1):13.

PMID: 35074011 PMC: 8785567. DOI: 10.1186/s40168-021-01205-8.